Drug Discovery 2017 Conference

March 27-28, 2017 - London, United Kingdom

Conference Proceedings

Standard Price

US$ 623.75

User Details

The gap between a laboratory discovery and an approved drug on the market is a decade-long process of laboratory testing, evaluation in animal models and human clinical trials that can cost hundreds of millions.

Against this backdrop our Drug Discovery 2017 aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.

Key Highlights:

  • discussions on the use of CRISPR/Cas9 Technology in target discovery, hit finding and translational studies;
  • success stories on phenotyping screening;
  • debates as to whether translational medicine is capable of increasing success rate in pharma;
  • insights into receptor activation from agonist and antagonist structures;
  • examples of applications of enabling chemistry technology to the acceleration of the drug discovery process.

Plus Two Interactive Post-Conference Workshops | Wednesday 29th March 2017

Workshop A: New Approaches in lead generation: towards drugs for every targets?
Leaders: Patrick Jimonet, External Opportunities in Early Drug Discovery, Sanofi
Eric Valeur, Associate Director, New Modalities & Lead Generation, AstraZeneca
08.30am - 12.30pm

Workshop B: Applications of physicochemical and biomimetic properties of molecules in early drug discovery
Leader: Klara Valko, Director, Bio-Mimetic Chromatography Consultancy, Honorary Professor, UCL School of Pharmacy
13.30pm - 17.30pm


  • Anthony Nicholls, President, CEO, OpenEye Scientific Software
  • Guido Hanauer, Scientific Director Translational Medicine, Takeda
  • Helen Boyd, Associate Director, AstraZeneca
  • Lewis Vidler, Research Scientist, Eli Lilly & Co
  • Lorenz Mayr, Vice President and Global Head, Reagents & Assay Development, AstraZeneca
  • Marta Westwood, Senior Scientist, UCB Pharma Limited
  • Matthias Frech, Director Molecular Interactions and Biophysics, Merck KGaA
  • Michael Hennig, CEO, leadXpro AG
  • Nigel Swain, Senior Medicinal Chemist , Heptares Therapeutics
  • Reyk Horland, Head of Business Development, Tissuse G Mb H
  • Roderick Hubbard, Senior Fellow, Vernalis Research Ltd
  • Steffen Weinbrenner, Head Drug Discovery, Polyphor Ltd
  • Stephen Pickett, Senior Scientific Investigator, GSK Fellow, GlaxoSmithKline
  • Stevan Djuric, Senior Director Discovery Chemistry and Technology, AbbVie
  • Ulrich Schopfer, Executive Director, Integrated Lead Discovery Head, Novartis
  • Werngard Czechtizky, Section Head, Medicinal Chemistry, Sanofi-Aventis

Please fill in your name and email to receive the conference agenda of this event.

The agenda is available as PDf under downloads at the right side of the page.


Holiday Inn Kensington Forum
97 Cromwell Rd, Kensington, SW7 4DN
London, UK


Holiday Inn Kensington Forum
97 Cromwell Road
London, United Kingdom
Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Physical Event
Reference :ASDE-15649